Online inquiry

IVTScrip™ mRNA-Anti-IFNG, NI-0501(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12419MR)

This product GTTS-WQ12419MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets IFNG gene. The antibody can be applied in Hemophagocytic lymphohistiocytosis (HLH) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000619.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3458
UniProt ID P01579
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IFNG, NI-0501(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ12419MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10973MR IVTScrip™ mRNA-Anti-IL17A&IL17F, MCAF-5352A(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MCAF-5352A
GTTS-WQ9429MR IVTScrip™ mRNA-Anti-KLRC1, IPH-2201(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IPH-2201
GTTS-WQ15380MR IVTScrip™ mRNA-Anti-CD37, TRU-016(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA TRU-016
GTTS-WQ9396MR IVTScrip™ mRNA-Anti-PTPRC, Iomab-B(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Iomab-B
GTTS-WQ5949MR IVTScrip™ mRNA-Anti-IGHE, CL-2C(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CL-2C
GTTS-WQ13648MR IVTScrip™ mRNA-Anti-CD19, RB4v1.2(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA RB4v1.2
GTTS-WQ3780MR IVTScrip™ mRNA-Anti-Factor VIIa substitute, BAY-86-6150(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BAY-86-6150
GTTS-WQ2541MR IVTScrip™ mRNA-Anti-GCGR, AMG 477(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG 477
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW